ADORA2A and Parkinson disease: The translational potential of A2AR antagonists is further enhanced by the recent demonstration of the safety profiles of the A2AR antagonist KW6002 in clinical phase III trials for motor benefit in >3500 Parkinson’s disease patients (Chen et al., 2013) and by regular consumption of caffeine (a non-specific adenosine A2AR and A1R antagonist) by 50% world population.